Ruth worked for more than 18 years at Johnson & Johnson. Ms. Voor was the Executive Director of Drug Eluting Stent Commercialization for J&J, leading the team that took CYPHER® Drug Eluting Stent from concept to launch and global approval in less than 4 years, achieving $1B in US sales in the first 9 months. She received a BS from the United States Naval Academy.

Dr. Voor is the Director of the Orthopaedic Bioengineering Laboratory at the University of Louisville. He has over 60 peer-reviewed publications, has secured over $3M in research funding and consulted on projects with many large orthopedic companies. Dr. Voor has authored several patents and has a bone fixation device, which is sold by DePuy Spine, Inc. He received his PhD from Tulane University’s Department of Biomedical Engineering.

Mark has extensive experience leading commercial organizations within the medical device industry. Previously, he was Senior Director of Sales and Marketing at DCI Donor Services, leading the commercialization within the orthopedics, spine and wound care market segments. Mr. Wagner also held leadership positions at AmerisourceBergen, Angiotech Pharmaceuticals and RTI Surgical. He received his MBA from Northwestern (Kellogg).